MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.
You may also be interested in...
Preliminary data from IQVIA suggest 2020 was one of the weakest in recent years for new launch trajectories although drug companies tell Scrip there are some lessons learned from promoting during the pandemic.
The company's CEO talked to Scrip about the expected US launch of tisotumab vedotin likely later in 2021 and the company's partnering strategy going forward.
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.